原標題：食物過敏表皮免疫治療現(xiàn)狀
 　?、?近年來食物過敏的流行導致急需尋找安全有效的免疫治療方式；② 皮膚免疫治療（EPIT）在小鼠中的研究得到了安全有效的數(shù)據(jù)；③ 小鼠模型還發(fā)現(xiàn)了一些可能對食物過敏原產(chǎn)生耐受性機制，包括調節(jié)性T細胞的誘導；④ 該方面研究目前缺乏臨床資料，但在一些小型的早期研究表明，對于花生和牛奶的過敏患者，EPIT比其他特異性變應原免疫治療方法更具有安全性；⑤ 該療法的目的是防止意外暴露于已知的食物過敏原。


　　延伸閱讀


Clinical Reviews in Allergy & Immunology
The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive Review
DOI: org/10.1007/s12016-017-8650-3
Abstract:
The food allergy epidemic of recent years has led to the search for safe and effective methods of immunotherapy for foods. Studies of epicutaneous immunotherapy (EPIT) in mice have shown promising safety and efficacy data. Murine models have also identified probable mechanisms for the development of tolerance to food allergens, including the induction of regulatory T cells. Clinical data is lacking, but relatively small and early studies among peanut and cow’s milk allergic subjects suggest that EPIT has an excellent safety profile,particularly compared to other methods of specific allergen immunotherapy. Efficacy data are also promising for peanut allergy, among younger patients (ages 4–11 years of age),suggesting that a majority of young patients will experience an increase in reaction threshold with therapy. The goal of this therapy is the protection from accidental exposures to a known food allergen. Additional clinical data is needed to prove efficacy and further demonstrate the safety profile of EPIT for food allergy, prior to approval by the Food and Drug Administration.
First Author:
Bruce J. Lanser
Correspondence:
National Jewish Health
All Authors:
Bruce J. Lanser,  Donald Y. M. Leung
　　創(chuàng)建過敏性疾病的科研、科普知識交流平臺，為過敏患者提供專業(yè)診斷、治療、預防的共享平臺。